Pharmacokinetics and Safety of SAR441236

Stopped early · Phase 1 · Has a placebo group

Conditions studied: HIV-1-infection

In brief

The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against the human immunodeficiency virus (HIV).

Key facts

Study ID
NCT03705169
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
52
Starts
2019-05-20
Expected to finish
2022-04-04
Last updated by the study team
2024-01-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.